Clinical trials
Trials in Bosnia and Herzegovina with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
16 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 2 |
| 2009 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 16 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University Clinical Centre of Republic of Srpska | 2 |
| University of Banja Luka | 2 |
| AtheroGenics | 1 |
| Can-Fite BioPharma | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| Heart Center BH Tuzla | 1 |
| Institute for Public Health of the Federation of Bosnia and Herzegovina | 1 |
| Josip Juraj Strossmayer University of Osijek | 1 |
| Poniard Pharmaceuticals | 1 |
| Public Health Foundation of India | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| COVID-19 | 2 |
| Diabetes Mellitus, Type 2 | 2 |
| Acute Coronary Syndrome | 1 |
| Arthritis, Rheumatoid | 1 |
| Asphyxia Neonatorum | 1 |
| Bacteremia | 1 |
| Breast Neoplasms | 1 |
| Cardiovascular Diseases | 1 |
| Celiac Disease | 1 |
| Diabetes Mellitus | 1 |
Trials
Showing 51 to 16 of 16. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.